[go: up one dir, main page]

CR9520A - Inhibidores de la fosfolipasa a2 citosolica - Google Patents

Inhibidores de la fosfolipasa a2 citosolica

Info

Publication number
CR9520A
CR9520A CR9520A CR9520A CR9520A CR 9520 A CR9520 A CR 9520A CR 9520 A CR9520 A CR 9520A CR 9520 A CR9520 A CR 9520A CR 9520 A CR9520 A CR 9520A
Authority
CR
Costa Rica
Prior art keywords
phospholipase
inhibitors
citosolica
enzymes
cytosolic
Prior art date
Application number
CR9520A
Other languages
English (en)
Inventor
C Mckew John
L Lee Katherine
Chen Lilhren
Vargas Richard
D Clark James
Williams Cara
Clerin Valerie
Marusic Suzana
Pong Kevin
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR9520A publication Critical patent/CR9520A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invencion provee inhibidores quimicos de la actividad de diversas enzimas fosfolipasa, particularmente de las enzimas fosfolipasa A2 citosolica (cpla2), mas particularmente incluyendo inhibidores de las enzimas fosfolipasa A2 alfa citosolica (cpla2a)
CR9520A 2005-05-27 2007-11-14 Inhibidores de la fosfolipasa a2 citosolica CR9520A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68556405P 2005-05-27 2005-05-27

Publications (1)

Publication Number Publication Date
CR9520A true CR9520A (es) 2008-02-20

Family

ID=37188759

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9520A CR9520A (es) 2005-05-27 2007-11-14 Inhibidores de la fosfolipasa a2 citosolica

Country Status (32)

Country Link
US (3) US7557135B2 (es)
EP (2) EP2248801A1 (es)
JP (1) JP5116666B2 (es)
KR (1) KR101353982B1 (es)
CN (2) CN102040550B (es)
AR (1) AR054195A1 (es)
AT (1) ATE489364T1 (es)
AU (1) AU2006251946B2 (es)
BR (1) BRPI0610049A2 (es)
CA (1) CA2607857C (es)
CR (1) CR9520A (es)
CY (1) CY1111151T1 (es)
DE (1) DE602006018451D1 (es)
DK (1) DK1891006T3 (es)
ES (1) ES2354908T3 (es)
GT (1) GT200600228A (es)
HN (1) HN2006019513A (es)
IL (1) IL186912A (es)
MX (1) MX2007014589A (es)
MY (1) MY144672A (es)
NI (1) NI200700287A (es)
NO (1) NO20075627L (es)
NZ (1) NZ563736A (es)
PE (1) PE20061426A1 (es)
PL (1) PL1891006T3 (es)
PT (1) PT1891006E (es)
RU (1) RU2433997C2 (es)
SI (1) SI1891006T1 (es)
SV (1) SV2008002551A (es)
TW (1) TW200718687A (es)
UA (1) UA91053C2 (es)
WO (1) WO2006128142A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605156B2 (en) * 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
HN2004000536A (es) 2003-12-16 2009-02-18 Wyeth Corp Un procediemiento de sintesis para la alquilacion reductiva de la posicon c-3 de indoles
IL161579A0 (en) 2004-04-22 2004-09-27 Mor Research Applic Ltd ANTISENSE OLIGONUCLEOTIDES AGAINST cPLA2, COMPOSITIONS AND USES THEREOF
CA2564868C (en) 2004-04-28 2013-11-26 Molecules For Health, Inc. Methods for treating or preventing restenosis and other vascular proliferative disorders
TW200718687A (en) 2005-05-27 2007-05-16 Wyeth Corp Inhibitors of cytosolic phospholipase A2
WO2007140317A2 (en) * 2006-05-26 2007-12-06 Wyeth Use of inhibitors of cytosolic ph0sph0lipase a2 in the treatment of thrombosis
IL178401A (en) * 2006-09-28 2012-04-30 Univ Ben Gurion Use of antisense oligonucleotides against 2 cPLA in the treatment of cancer
BRPI0717943A2 (pt) * 2006-10-31 2013-10-29 Wyeth Corp Composição farmacêutica; forma de dosagem farmacêutica; processo para a preparação de uma composição farmacêutica; e produto preparado pelo processo
CL2007003146A1 (es) * 2006-10-31 2008-01-25 Wyeth Corp Composición farmacéutica que comprende un compuesto derivado de indol y un sistema portador que comprende 15-25% de un mejorador de la viscosidad, 5-15% de un solubilizante, 10-50% de un diluyente y 1-10% de un estabilizante; proceso de preparación; y forma de dosificación.
BRPI0809542A8 (pt) 2007-03-29 2015-09-15 Asubio Pharma Co Ltd Compostos derivados de indol tendo atividade de inibição de cpla2, composição farmacêutica, e métodos de produção dos referidos compostos
US9526707B2 (en) 2007-08-13 2016-12-27 Howard L. Elford Methods for treating or preventing neuroinflammation or autoimmune diseases
KR101931628B1 (ko) 2010-06-18 2019-03-13 화이트헤드 인스티튜트 포 바이오메디칼 리서치 항바이러스 화합물에 대한 타켓인 pla2g16
EP2614144B1 (en) 2010-09-08 2015-07-22 Twincore Zentrum für Experimentelle und Klinische Infektionsforschung GmbH Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection
GB201401904D0 (en) * 2014-02-04 2014-03-19 Ziarco Pharma Ltd Pharmaceutical composition for topical administration
US9815768B2 (en) 2014-02-28 2017-11-14 Sumitomo Chemical Company, Limited Method for producing 2-(halogenomethyl)-3-methylnitrobenzene
CN103804150A (zh) * 2014-03-01 2014-05-21 江苏斯威森生物医药工程研究中心有限公司 一种3,4-二甲氧基苄基溴的制备方法
CN108017522B (zh) * 2017-11-16 2021-01-05 贵州大学 一种2,6-二溴苯甲磺酰氯的制备工艺
US20220220482A1 (en) * 2019-05-20 2022-07-14 Saint Louis University Reprogramming of lipid metabolism to inhibit t cell senescence and enhance tumor immunotherapy
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
EP4126231A1 (en) 2020-03-30 2023-02-08 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
TWI778562B (zh) 2020-04-02 2022-09-21 美商基利科學股份有限公司 製備cot抑制劑化合物的方法
US20230338529A1 (en) * 2020-08-06 2023-10-26 The Children's Medical Center Corporation Compositions for altering a microglial cell, and methods of use therefore

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH48411A (fr) 1909-07-19 1910-10-17 Stephen Alley Outillage pour mettre en place et enlever les bandages élastiques des roues de véhicules
GB1148909A (en) * 1965-04-19 1969-04-16 Sumitomo Chemical Co Process for production of novel phenylhydrazone and phenylhydrazine derivatives
FR1492929A (fr) 1966-05-11 1967-08-25 Roussel Uclaf Nouveaux 1-(omega-carboxyalcoyl) indoles substitués et procédé de préparation
US3505354A (en) * 1967-05-18 1970-04-07 Geigy Chem Corp 2-methyl-3-p-halobenzoylindole-n-aliphatic acids
DE1816335A1 (de) 1968-12-21 1970-07-09 Thiemann Gmbh Chem Pharm Fabri Verfahren zur Herstellung von [2-Methyl-5-alkoxy-3-acyl-indol-1]-essigsaeuren und deren Estern
US3931229A (en) * 1973-08-23 1976-01-06 Warner-Lambert Company 3-Thiomethyl-2[2-(dialkylamino)ethyl]indoles
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4271263A (en) * 1980-05-15 1981-06-02 Minnesota Mining And Manufacturing Company Thermally developable photosensitive compositions containing acutance agents
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4654360A (en) * 1984-06-01 1987-03-31 Syntex (U.S.A.) Inc. 1,2,3-trisubstituted indoles for treatment of inflammation
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4894386A (en) * 1987-04-15 1990-01-16 Ici Americas Inc. Aliphatic carboxamides
ES2045420T3 (es) 1988-04-13 1994-01-16 Ici America Inc Amidas ciclicas.
GB8906032D0 (en) 1988-04-14 1989-04-26 Ici America Inc Hetera-aliphatic carboxamides
US5166170A (en) * 1989-07-03 1992-11-24 Hoechst-Roussel Pharmaceuticals Incorporated 2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders
GB8916774D0 (en) * 1989-07-21 1989-09-06 Bayer Ag New indole derivatives,a process for their preparation and their use in medicaments
PT95692A (pt) 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5229516A (en) * 1989-10-27 1993-07-20 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5081145A (en) * 1990-02-01 1992-01-14 Merck Frosst Canada, Inc. Indole-2-alkanoic acids compositions of and anti allergic use thereof
US5622832A (en) * 1990-02-28 1997-04-22 Genetics Institute, Inc. Arachidonic acid releasing phospholipase A2 enzyme and methods of use
US5190968A (en) * 1991-09-30 1993-03-02 Merck Frosst Canada, Inc. (Polycyclic-arylmethoxy) indoles as inhibitors of leukotriene biosynthesis
US5290798A (en) 1991-09-30 1994-03-01 Merck Frosst Canada, Inc. (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5206377A (en) 1991-12-05 1993-04-27 Whitby Research, Inc. Compounds useful as antiproliferative agents
NZ249729A (en) 1992-05-13 1996-12-20 Syntex Inc Substituted indoles and azaindoles, preparation and pharmaceutical compositions thereof
US5212195A (en) * 1992-05-13 1993-05-18 Syntex (U.S.A.) Inc. Substituted indole antagonists derivatives which are angiotensin II
US5288743A (en) * 1992-11-20 1994-02-22 Abbott Laboratories Indole carboxylate derivatives which inhibit leukotriene biosynthesis
ZA939516B (en) 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
DE4338770A1 (de) 1993-11-12 1995-05-18 Matthias Dr Lehr Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶
US5686481A (en) * 1993-12-21 1997-11-11 Smithkline Beecham Corporation Endothelin receptor antagonists
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
US5482960A (en) * 1994-11-14 1996-01-09 Warner-Lambert Company Nonpeptide endothelin antagonists
JP2000515529A (ja) 1996-08-01 2000-11-21 メルクル・ゲーエムベーハー 細胞質ホスホリパーゼａ▲下２▼の阻害剤としてのアシルピロリドンジカルボン酸およびアシルインドールジカルボン酸ならびにその誘導体
US6630496B1 (en) * 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
CA2264020A1 (en) 1996-08-26 1998-03-05 Jean Bemis Inhibitors of phospholipase enzymes
US5994398A (en) 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
HUP0100156A3 (en) 1998-02-25 2002-12-28 Genetics Inst Inc Cambridge Indole derivatives as inhibitors of phospholipase a2 and use of them for producing pharmaceutical compositions
JP2002504541A (ja) 1998-02-25 2002-02-12 ジェネティックス・インスチチュート・インコーポレーテッド ホスホリパーゼ酵素阻害剤
JP2002504539A (ja) * 1998-02-25 2002-02-12 ジェネティックス・インスチチュート・インコーポレーテッド ホスホリパーゼ酵素の阻害剤
US6500853B1 (en) * 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
WO2000044723A1 (en) 1999-01-27 2000-08-03 American Cyanamid Company Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors
US6424105B1 (en) 1999-06-08 2002-07-23 Camco International, Inc. Real-time control of feedback signals to a motor for optimum performance
EP1277767A4 (en) * 2001-01-22 2006-09-20 Sony Corp SOLVENT ABSORBENT RESIN AND METHOD FOR THE PRODUCTION THEREOF
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
US7605156B2 (en) * 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US6797708B2 (en) 2001-12-03 2004-09-28 Wyeth Inhibitors of cytosolic phospholipase A2
EP1451154B1 (en) * 2001-12-03 2008-01-16 Wyeth Inhibitors of cytosolic phospholipase a2
US6984735B2 (en) * 2001-12-03 2006-01-10 Wyeth Process for making an aldehyde
US7101875B2 (en) * 2001-12-03 2006-09-05 Wyeth Methods for treating arthritic disorders
US6635771B2 (en) * 2001-12-03 2003-10-21 Wyeth N-benzhydryl indole compounds
US7439249B2 (en) * 2002-12-31 2008-10-21 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatases
CA2511925C (en) 2002-12-31 2012-11-13 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of phosphatases, compositions and uses thereof
TW200510305A (en) 2003-07-25 2005-03-16 Wyeth Corp Process for the preparation of CPLA2 inhibitors
US7582771B2 (en) * 2003-09-03 2009-09-01 Wyeth Process for the synthesis of cPLA2 inhibitors
WO2005023201A2 (en) 2003-09-09 2005-03-17 Medarex, Inc. Methods for treating rheumatoid arthritis
US7342119B2 (en) * 2003-09-30 2008-03-11 Wyeth Holdings Corporation Process for the synthesis of a CPLA2 inhibitor
HN2004000536A (es) 2003-12-16 2009-02-18 Wyeth Corp Un procediemiento de sintesis para la alquilacion reductiva de la posicon c-3 de indoles
AR053410A1 (es) * 2004-08-19 2007-05-09 Wyeth Corp Proceso para la sintesis de indoles n-alquilados c-2, c-3 sustituidos. compuestos intermediarios
TW200718687A (en) 2005-05-27 2007-05-16 Wyeth Corp Inhibitors of cytosolic phospholipase A2
WO2007140317A2 (en) 2006-05-26 2007-12-06 Wyeth Use of inhibitors of cytosolic ph0sph0lipase a2 in the treatment of thrombosis

Also Published As

Publication number Publication date
NI200700287A (es) 2008-05-27
US7557135B2 (en) 2009-07-07
CN102040550A (zh) 2011-05-04
GT200600228A (es) 2006-12-26
TW200718687A (en) 2007-05-16
WO2006128142A8 (en) 2007-12-27
US20100029645A1 (en) 2010-02-04
PE20061426A1 (es) 2007-01-24
JP5116666B2 (ja) 2013-01-09
DK1891006T3 (da) 2011-01-24
PL1891006T3 (pl) 2011-05-31
RU2433997C2 (ru) 2011-11-20
HK1152710A1 (en) 2012-03-09
CA2607857A1 (en) 2006-11-30
AR054195A1 (es) 2007-06-06
SV2008002551A (es) 2008-07-23
DE602006018451D1 (de) 2011-01-05
WO2006128142A3 (en) 2007-03-29
BRPI0610049A2 (pt) 2010-05-25
CN101184729B (zh) 2011-02-16
US20070004719A1 (en) 2007-01-04
US8283373B2 (en) 2012-10-09
HK1113680A1 (en) 2008-10-10
AU2006251946B2 (en) 2011-05-12
IL186912A0 (en) 2008-02-09
NZ563736A (en) 2010-11-26
RU2007140910A (ru) 2009-07-10
CA2607857C (en) 2014-02-11
ATE489364T1 (de) 2010-12-15
KR101353982B1 (ko) 2014-02-18
MX2007014589A (es) 2008-01-21
CN101184729A (zh) 2008-05-21
MY144672A (en) 2011-10-31
NO20075627L (no) 2008-01-03
WO2006128142A2 (en) 2006-11-30
UA91053C2 (en) 2010-06-25
PT1891006E (pt) 2011-01-26
US20100022536A1 (en) 2010-01-28
HN2006019513A (es) 2011-03-02
EP2248801A1 (en) 2010-11-10
JP2008542303A (ja) 2008-11-27
AU2006251946A1 (en) 2006-11-30
CN102040550B (zh) 2012-10-03
ES2354908T3 (es) 2011-03-21
SI1891006T1 (sl) 2011-02-28
EP1891006A2 (en) 2008-02-27
EP1891006B1 (en) 2010-11-24
IL186912A (en) 2012-05-31
CY1111151T1 (el) 2015-06-11
KR20080021618A (ko) 2008-03-07

Similar Documents

Publication Publication Date Title
CR9520A (es) Inhibidores de la fosfolipasa a2 citosolica
HN2003000227A (es) Inhibidores de quinasas
EA200701918A1 (ru) Белок липокалин
NO20071309L (no) Fremgangsmate for ekspansjon
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
DK1848718T3 (da) E1 aktiveringsenzymhæmmere
NO20044597L (no) Kjemiske forbindelser
MY144590A (en) Glutamate aggrecanase inhibitors
PA8618901A1 (es) Biaril sulfonamidas y metodo para el uso de las mismas
CR8312A (es) Nuevas sulfonamidas como agentes fitosanitarios
EP1941060A4 (en) PROTEIN DEMETHYLASES WITH A JMJC DOMAIN
EP1817276A4 (en) CATHEPSINCYSTEINPROTEASEHEMMER
PA8667201A1 (es) Nuevos compuestos farmaceuticos
DK2179035T3 (da) Modificeret bakteriofag omfattende et alfa/beta-sasp-(small acid-soluble spore protein)-gen
SV2006002001A (es) Inhibidores de quinasa ref. x - 16437
DE602005018653D1 (de) Aktive auswahl der bestätigungsquelle
EP1772148A4 (en) Lipase inhibitors
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
EP1767205A4 (en) LIPASE INHIBITORS
CR8813A (es) Nueva asociacion de un inhibidor de la corriente sinusual l1 y de un inhibidor calcico y las composiciones farmaceuticas que la contienen
EP1704861A4 (en) lipase
PA8795401A1 (es) Asociacion entre un antiaterotrombotico y un inhibidor de la enzima de conversion de la angiotensina
DK1912954T3 (da) Hidtil ukendte cysteinproteaseinhibitorer og deres terapeutiske applikationer
PA8645401A1 (es) Procedimiento de fabricacion de compuestos imidazolicos, sus sales y sus pseudopolimorfos
ATE462574T1 (de) Abbildungskopfhalterung

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)